New shot could replace daily pill for advanced breast cancer
NCT ID NCT07340658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial compares an injectable form of letrozole (given every 3 months) to the standard daily oral pill, both combined with ribociclib, in 300 postmenopausal women with advanced HR-positive, HER2-negative breast cancer. The goal is to see if the injection works as well as the pill in delaying cancer growth. Participants will be randomly assigned to receive either the injection plus a dummy pill, or the real pill plus a dummy injection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Letrozole (injectable) and ribociclib
- What this could lead to
- If it works, this could offer a more convenient treatment option for advanced breast cancer, potentially improving quality of life.
- What could go wrong
- This is a phase 3 trial, but it's not yet recruiting. The new injectable form may not be as effective or safe as the standard oral drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
- New cocktail of drugs aims to keep HER2+ breast cancer in check
- New trial aims to beat cancer fatigue with common drug
- Blood test study aims to unlock secrets of Hard-to-Treat breast cancer
- Breast cancer drug IBRANCE® under Real-World watch in korea
- New drug combo shows promise in early breast cancer trial